---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-005186"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2022-07-28T23:59:59+00:00"
generated_at: "2026-06-24T07:18:05.577138+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte Biotech rejects Iroquois Capital's consent solicitation to control board and cash reserves

## Summary
- Iroquois Capital, a 7% holder, seeks to expand board from 7 to 15 and elect 8 nominees to gain control of $80M+ cash.
- Company says Iroquois proposals are full of factual inaccuracies and would disenfranchise shareholders; urges ignoring consent cards.
- PharmaCyte states Iroquois slate has limited biopharma experience; claims seven similar Iroquois board additions led to avg 30%+ stock decline.
- Company reports ~90% of FDA clinical hold requests completed; two-phase pig study is last major item, progress could be jeopardized.
- PharmaCyte engaged in settlement talks with Iroquois but they rejected; Iroquois bought shares at low price and sold immediately, per company.

## SEC filing metadata
- accession: 0001683168-22-005186
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2022-07-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005186/0001683168-22-005186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005186/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-005186
- JSON: https://secwatch.observer/filing/0001683168-22-005186.json
- Plain text: https://secwatch.observer/filing/0001683168-22-005186.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.